Syndax Pharmaceuticals
SNDX
132 hedge funds and large institutions have $1.15B invested in Syndax Pharmaceuticals in 2021 Q4 according to their latest regulatory filings, with 30 funds opening new positions, 42 increasing their positions, 34 reducing their positions, and 20 closing their positions.
599% more call options, than puts
Call options by funds: $5.77M | Put options by funds: $825K
50% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 20
24% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 34
22% more capital invested
Capital invested by funds: $938M → $1.15B (+$209M)
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
7% more funds holding
Funds holding: 123 → 132 (+9)
1.15% less ownership
Funds ownership: 100.92% → 99.77% (-1.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$33.1M |
| 2 |
FM
Frazier Management
Seattle,
Washington
|
+$29.3M |
| 3 |
ACA
Avoro Capital Advisors
New York
|
+$11.6M |
| 4 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$9.93M |
| 5 |
Norges Bank
Oslo,
Norway
|
+$8.96M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Boxer Capital
San Diego,
California
|
-$43.7M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$30.8M |
| 3 |
CC
Casdin Capital
New York
|
-$22.9M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$9.86M |
| 5 |
BI
BVF Inc
San Francisco,
California
|
-$7.15M |
SNDX Hedge Fund Activity: Q4 2021 in Review
132 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Syndax Pharmaceuticals (SNDX) for Q4 2021, worth a combined $1.15B — up 22% from $938M a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new SNDX positions and 20 closed out — a net gain of 10 holders — while 42 added to existing stakes and 34 trimmed.
The largest buyer was OrbiMed, adding an estimated $33.1M. The largest seller was Boxer Capital, exiting entirely with an estimated $43.7M sold.
- 132 institutional investors held Syndax Pharmaceuticals (SNDX) as of Q4 2021, up from 123 in Q3 2021.
- Funds reported $1.15B of Syndax Pharmaceuticals stock for Q4 2021, up 22% quarter-over-quarter.
- 30 funds opened new Syndax Pharmaceuticals positions in Q4 2021 and 20 closed out, a net change of +10 holders.
- The largest Syndax Pharmaceuticals buyer in Q4 2021 was OrbiMed, an estimated $33.1M added.
- The largest Syndax Pharmaceuticals seller in Q4 2021 was Boxer Capital, an estimated $43.7M sold.
Based on aggregated 13F filings for Q4 2021.